AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to ...

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...

AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.